Drishti Discoveries

Executive Summary

Drishti Discoveries is a London-based biotechnology company founded in 2020, applying artificial intelligence and computational biology to discover novel drug targets for neurological disorders. The company’s core platform utilizes artificial microRNA (miRNA) to achieve sustained gene knockdown via RNA interference combined with gene therapy, aiming to address neurodegenerative diseases. By leveraging a proprietary computational discovery engine, Drishti identifies high-value targets and designs RNA-based therapeutics that can be delivered using AAV vectors. This approach promises long-lasting effects with a single administration, potentially overcoming key limitations of conventional small-molecule or antibody therapies for chronic neurological conditions. The company is privately held and, as of early 2026, has not disclosed funding rounds or pipeline details publicly. Drishti's technology is positioned at the intersection of two rapidly advancing fields: RNA therapeutics and AI-driven drug discovery. The artificial miRNA platform offers advantages over traditional RNAi approaches, including improved specificity, reduced off-target effects, and durable target suppression. While still in preclinical stages, the company’s focus on neurodegenerative diseases—a high-unmet-need area—and its differentiated delivery strategy could attract strong interest from partners and investors. Key challenges include demonstrating in vivo proof-of-concept, manufacturing scalability, and navigating the regulatory landscape for RNA-based gene therapies. With no disclosed financing or partnerships, Drishti is likely seeking seed or Series A funding to advance its lead programs toward the clinic.

Upcoming Catalysts (preview)

• Q1 2027Preclinical Proof-of-Concept Data for Lead Neurodegenerative Program40% success
• Q4 2026Series A Financing or Major Partnership Announcement60% success
• Q2 2027IND-Enabling Studies Initiation or Regulatory Milestone25% success